Literature DB >> 3022907

Nongerminomatous malignant germ cell tumors in children. A review of 89 cases from the Pediatric Oncology Group, 1971-1984.

E P Hawkins, M J Finegold, H K Hawkins, J P Krischer, K A Starling, A Weinberg.   

Abstract

Clinical and morphologic features of 89 cases of childhood yolk sac tumor (YS) and embryonal carcinoma (EC) (29 associated with teratomas) submitted to the Rare Tumor Registry of the Southwest Oncology Group (1971-1979) or the Pediatric Oncology Group (1980-1984) between 1971 and 1984 were reviewed and submitted to statistical analysis. This review showed an improved survival for each 5-year period regardless of tumor site, no statistically significant difference between "pure" tumors and those mixed with other teratomatous components, no statistically significant difference between YS and EC in children, a better than reported prognosis for sacrococcygeal tumors occurring after the neonatal period, a particularly poor prognosis for neonatal "benign" sacrococcygeal teratomas resected without coccygectomy when they recur as YS, excellent survival for all testicular tumors regardless of age or the presence of EC, and the occurrence of mediastinal tumors in females.

Entities:  

Mesh:

Year:  1986        PMID: 3022907     DOI: 10.1002/1097-0142(19861215)58:12<2579::aid-cncr2820581204>3.0.co;2-v

Source DB:  PubMed          Journal:  Cancer        ISSN: 0008-543X            Impact factor:   6.860


  3 in total

1.  Sacrococcygeal yolk sac carcinoma: imaging findings during treatment.

Authors:  S C Kaste; J O Bridges; N M Marina
Journal:  Pediatr Radiol       Date:  1996

Review 2.  Pure yolk sac tumor of sacrococcygeal region.

Authors:  Rashim Sharma; Sudeep Khera; Arvind Sinha; Taruna Yadav
Journal:  Autops Case Rep       Date:  2021-05-25

3.  Successful radiotherapy in postoperative recurrence of a primary mediastinal yolk sac tumor: A case report.

Authors:  Masakuni Sakaguchi; Toshiya Maebayashi; Takuya Aizawa; Naoya Ishibashi; Shoko Fukushima; Tsutomu Saito
Journal:  Thorac Cancer       Date:  2015-08-20       Impact factor: 3.500

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.